IP Library Granted Patent US 11,021,737
Granted Patent B2
US 11,021,737 · App. 16/941,585 · Granted Jun 1, 2021

Compositions and methods for analyte detection

Inventors: George M. Church (Brookline, MA); Je-hyuk Lee (Allston, MA); Daniel Levner (Boston, MA); Michael Super (Lexington, MA)
Assignee: President and Fellows of Harvard College
C12Q1/6806C12P19/34C12Q1/6844C12Q1/6869C12Q1/6874
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,021,737
App. No.
16/941,585
Granted
Jun 1, 2021
Kind
B2
Abstract

Methods of making a three-dimensional matrix of nucleic acids within a cell is provided.

Claims (56)

1. A method for identifying an analyte, comprising:

(a) contacting a cell or tissue sample comprising said analyte with a detection reagent, wherein said detection reagent comprises (i) a probe that binds to said analyte and (ii) a nucleic acid label comprising one or more pre-determined subsequences;

(b) detecting a temporal order of signal signatures in said cell or tissue sample, wherein said temporal order of signal signatures is associated with said one or more pre-determined subsequences; and

(c) using said temporal order of signal signatures to identify said analyte in said cell or tissue sample.

2. The method of claim 1 , wherein said cell or tissue sample is immobilized on a solid support.

3. The method of claim 1 , wherein said probe is a nucleic acid, an antibody, an enzyme, an antigen, a small molecule, a protein, a peptide, a peptidomimetic, a sugar, a carbohydrate, a lipid, a glycan, a glycoprotein, an aptamer or any combination thereof.

4. The method of claim 1 , wherein said probe comprises an antibody or an antigen-binding fragment of an antibody.

5. The method of claim 1 , wherein said detecting comprises sequencing said one or more pre-determined subsequences.

6. The method of claim 5 , wherein said sequencing comprises sequencing-by-synthesis.

7. The method of claim 5 , wherein said sequencing comprises sequencing-by-ligation.

8. The method of claim 1 , wherein said nucleic acid label comprises a first pre-determined subsequence and a second pre-determined subsequence, and wherein said temporal order of signal signatures comprises signal signatures associated with sequences of said first pre-determined subsequence and said second pre-determined subsequence.

9. The method of claim 1 , wherein said probe is covalently coupled to said nucleic acid label.

10. The method of claim 1 , wherein (b) comprises coupling decoder probes to said one or more pre-determined subsequences in a temporally-sequential manner.

11. The method of claim 1 , wherein said analyte is a ribonucleic acid (RNA) molecule.

12. The method of claim 1 , wherein (b) comprises hybridizing a plurality of labeled probes to sequences of said one or more pre-determined sequences, and sequentially detecting signal signatures from labeled probes of said plurality of labeled probes to provide said temporal order of signal signatures.

13. The method of claim 12 , wherein a labeled probe of said plurality of labeled probes comprises an optical label.

14. The method of claim 13 , wherein said optical label comprises a fluorescent label.

15. The method of claim 1 , wherein said probe is a nucleic acid.

16. The method of claim 15 , wherein said probe and said nucleic acid label are part of the same nucleic acid molecule.

17. The method of claim 1 , wherein each of said one or more pre-determined subsequences is 3-50 nucleotides in length.

18. The method of claim 8 , wherein said first pre-determined subsequence is 3-50 nucleotides in length and said second pre-determined subsequence 3-50 nucleotides in length.

19. The method of claim 2 , wherein said cell or tissue sample is a tissue section immobilized on said solid support.

20. The method of claim 19 , wherein said tissue section is derived from a fixed tissue.

21. The method of claim 19 , further comprising, prior to (a), permeabilizing said tissue section.

22. The method of claim 1 , wherein said cell or tissue sample is paraffin-embedded.

23. The method of claim 1 , wherein (a) comprises coupling an additional detection reagent to said analyte, wherein said additional detection reagent comprises (i) an additional probe that binds to said analyte and (ii) an additional nucleic acid label comprising an additional one or more pre-determined subsequences; and wherein said temporal order of signal signatures comprises signal signatures associated with sequences of said one or more pre-determined subsequences and said additional one or more pre-determined subsequences.

24. A method for biological analysis, comprising:

(a) providing a cell or tissue sample, wherein said cell or tissue sample comprises an analyte at a location of said cell or tissue sample;

(b) binding a detection reagent to said analyte at said location; wherein said detection reagent comprises (i) a probe that binds to said analyte and (ii) one or more pre-determined subsequences;

(c) detecting a temporal order of signal signatures at said location, wherein said temporal order of signal signatures is associated with said one or more pre-determined subsequences; and

(d) using said temporal order of signal signatures to identify said location of said analyte in said cell or tissue sample.

25. The method of claim 24 , wherein (c) comprises hybridizing a first decoder probe comprising a first detectable label to a first pre-determined subsequence of said one or more pre-determined subsequences; detecting said first detectable label to generate a first signal signature; hybridizing a second decoder probe comprising a second detectable label to a second pre-determined subsequence of said one or more pre-determined subsequences; and detecting said second detectable label to generate a second signal signature, wherein said first pre-determined subsequence and said second pre-determined subsequence are different sequences.

26. The method of claim 25 , wherein said first detectable label or said second detectable label comprises an optical label.

27. The method of claim 24 , wherein each of said one or more pre-determined subsequences are 3-50 nucleotides in length.

28. The method of claim 24 wherein said detecting comprises sequencing said one or more pre-determined subsequences.

29. The method of claim 28 wherein said sequencing comprises sequencing-by-synthesis.

30. The method of claim 28 , wherein said sequencing comprises sequencing-by-ligation.

31. The method of claim 24 , wherein said probe is a nucleic acid, an antibody, an antibody fragment, an enzyme, an antigen, an antigen-binding fragment, a small molecule, a protein, a peptide, a peptidomimetic, a sugar, a carbohydrate, a lipid, a glycan, a glycoprotein, an aptamer, or any combination thereof.

32. The method of claim 24 , wherein said probe comprises an antibody, an antibody fragment or an antigen-binding fragment that binds said analyte.

33. The method of claim 24 , wherein said probe comprises an aptamer that binds said analyte.

34. The method of claim 24 , wherein said one or more pre-determined subsequences comprises a first pre-determined subsequence and a second pre-determined subsequence, and wherein said temporal order of signal signatures comprises signal signatures associated with said first pre-determined subsequence and said second pre-determined subsequence.

35. The method of claim 34 , wherein said first pre-determined subsequence and said second pre-determined subsequence are conjugated together by a linker.

36. The method of claim 35 , wherein said first pre-determined subsequence and said second pre-determined subsequence are conjugated together by a phosphodiester bond or a nucleotidic linker.

37. The method of claim 24 , wherein said probe is a nucleic acid probe and wherein said probe and said one or more pre-determined subsequences are coupled together by a phosphodiester bond or a nucleotidic linker.

38. The method of claim 24 , wherein said detecting comprises coupling a plurality of labeled probes to sequences of said one or more pre-determined sequences, and sequentially detecting signal signatures from labeled probes of said plurality of labeled probes to provide said temporal order of signal signatures.

39. The method of claim 38 , wherein a labeled probe of said plurality of labeled probes comprises an optical label.

40. The method of claim 39 , wherein said optical label comprises a fluorescent label.

41. The method of claim 24 , wherein said analyte is a nucleic acid molecule and wherein said probe is a nucleic acid probe.

42. The method of claim 41 , wherein said nucleic acid molecule is a ribonucleic acid (RNA) molecule.

43. The method of claim 24 , wherein said cell or tissue sample is immobilized on a solid support.

44. The method of claim 43 , wherein said cell or tissue sample is a tissue section immobilized on said solid support.

45. The method of claim 44 , wherein said tissue section is derived from a fixed tissue.

46. The method of claim 44 , further comprising, prior to (b), permeabilizing said tissue section.

47. The method of claim 43 , wherein said cell or tissue sample is paraffin-embedded.

48. The method of claim 24 , wherein (b) comprises coupling an additional detection reagent to said analyte at said location, wherein said additional detection reagent comprises (i) an additional probe that binds to said analyte and (ii) an additional one or more pre-determined subsequences; and wherein said temporal order of signal signatures comprises signal signatures associated with sequences of said one or more pre-determined subsequences and said additional one or more pre-determined subsequences.

49. The method of claim 24 , wherein said one or more pre-determined subsequences form an identifier of said probe and wherein (d) comprises comparing said temporal order of signal signatures with said identifier, wherein an agreement between said temporal order of signal signatures and said identifier identifies said analyte.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 13, 2023
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065238/0071 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: CHURCH, GEORGE; LEE, JEHYUK; LEVNER, DANIEL; SUPER, MICHAEL
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 055711/0230 →
Continuity (8)
Continuation In Part 16157243 · Oct 11, 2018
Continuation 14774282
Continuation In Part 16393215 · Apr 24, 2019
Continuation 16255920 · Jan 24, 2019
Continuation 14366486
Provisional Application 61777383 · Mar 12, 2013
Provisional Application 61579265 · Dec 22, 2011
Related Publication 20200354774A1 · Nov 12, 2020
Cited By (24)
US 12,203,136 US 12,209,237 US 12,209,275 US 12,234,503 US 12,264,358 US 12,281,356 US 12,331,347 US 12,359,253 US 12,442,037 US 12,460,250 US 12,460,319 US 12,467,086 US 12,473,546 US 12,492,427 US 12,522,819 US 12,522,820 US 12,559,790 US 12,565,671 US 12,618,099 US 12,630,869 US 12,655,473 US 12,655,478 US 12,718,518 US 12,718,906